VASCEPA (icosapent ethyl) - (REDUCE-IT)

Aug. 24, 2026: Amarin Corporation plc (NASDAQ: AMRN) announced upcoming ESC Congress 2026 presentations (Aug. 28-31, Munich) on icosapent ethyl/EPA and the REDUCE-IT program in high cardiovascular-risk patients with hypertriglyceridemia.

Programs/abstracts:

• REDUCE-IT Legacy: “Adherence and Legacy Effects of High Dose Eicosapentaenoic Acid in Hypertriglyceridemia and High CV Risk,” moderated poster, available Aug. 28 at 10:15 CET.
• REDUCE-IT: “Sex Differences in Early Study Discontinuation and Study Drug Withdrawal,” moderated poster, available Aug. 28 at 14:15 CET.
• REDUCE-IT post hoc analysis: “Effects of Icosapent Ethyl on Coagulation Biomarkers and Their Association with Event-free Survival in High-risk Cardiovascular Patients,” moderated poster, available Aug. 30 at 10:15 CET.
• EPA/Lp(a) mechanistic research: “EPA Limits Rapid Oxidation of Lipoprotein(a) [Lp(a)] Yielding Favorable Changes in Endothelial Cell Protein Expression,” moderated poster, available Aug. 30 at 16:15 CET.
• REDUCE-IT Lp(a) Variability: oral presentation on lipoprotein(a) variability in high CV-risk patients with hypertriglyceridemia and controlled LDL-C on statins, available Aug. 28 at 10:45 CET.

The release describes these as Amarin-supported abstracts adding to evidence from REDUCE-IT and related research; no new clinical efficacy readout or regulatory decision was reported.